Sickle cell hemoglobin C disease patient undergoing coronary artery bypass grafting with complete exchange blood transfusion during cardiopulmonary bypass

2Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Sickle cell disorders are associated with increased risk of sickling and vaso-occlusive complications when undergoing cardiopulmonary bypass (CPB) surgery. Monitoring of certain parameters such as venous and arterial oxygen content, hematocrit, acid base homeostasis, and body temperature are required for a superior outcome. Furthermore, perioperative exchange transfusion has a positive effect on the outcome of surgery and on the survival of patients undergoing heart surgery. Avoiding intraoperative hypoxia and hypothermia, and minimizing hemoglobin S (HbS) and hemoglobin C (HbC) levels with exchange transfusion make bypass surgery relatively safe with enhanced outcomes in these cases. The exact HbS level for conducting cardiac surgery with CPB is not known, however, a HbS level <30% is considered safe for conducting CPB. By using a "discard" cardiotomy reservoir and priming the oxygenator reservoir with donor blood, we were able to reduce the intraoperative circulating HbS and HbC levels to less than 15% and sequester the plasma and clotting factors from the discarded blood using intraoperative plasmapheresis.

Cite

CITATION STYLE

APA

Mullins, F., Ott, S., Mister, N., & Travis, J. (2018). Sickle cell hemoglobin C disease patient undergoing coronary artery bypass grafting with complete exchange blood transfusion during cardiopulmonary bypass. In Journal of Extra-Corporeal Technology (Vol. 50, pp. 117–119). American Society of Extra-Corporeal Technology. https://doi.org/10.1051/ject/201850117

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free